Wilsons Report - 27c 12-month target, page-7

“Sarepta’s SRP-5051 exon 51 skipping drug produces a mean (mini) dystrophin expression of 5.17%, which is a lot more than eteplirsen.
It’s a next generation eteplirsen with a peptide for better delivery to muscle.
That level of minidystrophin may achieve improvements in walking beyond corticosteroids (CS) though that is still to be determined .
Sarepta’s Elevidys achieves 39-54% microdystrophin but does not improve walking endpoints beyond CS, likely because it’s a minidystrophin thats missing parts of dystrophin as they cant put the whole dystrophin gene in the Adenovirus vector. “

I hope this helps people understand that Sareptas drugs are not 100% given…
But
Even if the FDA approve Sarepta drugs they will still need Atl1102 to reduce Inflammation.
Inflammation is a key component which can make Sareptas and other drugs more potent.